{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T22:46:27Z","timestamp":1768430787239,"version":"3.49.0"},"reference-count":77,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The present review highlights the advances in disease outcome achieved with currently available biologic medications and future perspectives for JIA management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>In the last two decades, the management of juvenile idiopathic arthritis (JIA) has been revolutionized by appropriate legislative initiatives, the existence of very large collaborative networks and the increased availability of the novel biologic medications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>A more rational approach to the management of JIA is being fostered by the recent publication of therapeutic recommendations, consensus treatment plans and for a treat-to-target strategy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000632","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T13:35:07Z","timestamp":1559828107000},"page":"428-435","source":"Crossref","is-referenced-by-count":23,"title":["Treatment of juvenile idiopathic arthritis: what's new?"],"prefix":"10.1097","volume":"31","author":[{"given":"Gabriella","family":"Giancane","sequence":"first","affiliation":[{"name":"IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia \u2013 PRINTO"},{"name":"Universit\u00e0 degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia \u2013 PRINTO"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","article-title":"Juvenile idiopathic arthritis","volume":"377","author":"Prakken","year":"2011","journal-title":"Lancet"},{"key":"R3-20230829","first-page":"1991","article-title":"Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban","volume":"25","author":"Petty","year":"1998","journal-title":"J Rheumatol"},{"key":"R4-20230829","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification criteria for juvenile idiopathic arthritis: first steps, Pediatric Rheumatology International Trials Organization International Consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J Rheumatol"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/adc.2010.188946","article-title":"Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO)","volume":"96","author":"Ruperto","year":"2011","journal-title":"Arch Dis Child"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12969-018-0261-x","article-title":"Pediatric Rheumatology Collaborative Study Group - over four decades of pivotal clinical drug research in pediatric rheumatology","volume":"16","author":"Brunner","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0140-6736(17)30065-X","article-title":"Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial","volume":"389","author":"Ravelli","year":"2017","journal-title":"Lancet"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","article-title":"Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group","volume":"326","author":"Giannini","year":"1992","journal-title":"N Engl J Med"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/art.20288","article-title":"A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate","volume":"50","author":"Ruperto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","article-title":"Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial","volume":"77","author":"Brunner","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","article-title":"Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study","volume":"73","author":"Horneff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/acr.22961","article-title":"Risk of serious infection in juvenile idiopathic arthritis patients associated with tumor necrosis factor inhibitors and disease activity in the German Biologics in Pediatric Rheumatology Registry","volume":"69","author":"Becker","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12969-016-0126-0","article-title":"Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept","volume":"14","author":"Verazza","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/art.38042","article-title":"Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis","volume":"65","author":"Lovell","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1002\/art.39796","article-title":"Outcome and trends in treatment of systemic juvenile idiopathic arthritis in the german national pediatric rheumatologic database, 2000-2013","volume":"68","author":"Klotsche","year":"2016","journal-title":"Arthritis Rheum"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13075-017-1462-2","article-title":"Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry","volume":"19","author":"Horneff","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3899\/jrheum.130690","article-title":"Longterm safety and effectiveness of the antiinterleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan","volume":"41","author":"Yokota","year":"2014","journal-title":"J Rheumatol"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1136\/annrheumdis-2015-207818","article-title":"Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan","volume":"75","author":"Yokota","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.39407","article-title":"Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab","volume":"68","author":"Grom","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2012-202361","article-title":"Forget personalised medicine and focus on abating disease activity","volume":"72","author":"Smolen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nrrheum.2016.156","article-title":"Enhancing translational research in paediatric rheumatology through standardization","volume":"12","author":"Yeung","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"R33-20230829","first-page":"819","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international task force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/art.38615","article-title":"Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?","volume":"66","author":"Nigrovic","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R35-20230829","doi-asserted-by":"crossref","DOI":"10.1002\/art.40865","article-title":"Treat-to-target using first-line recombinant interleukin-1 receptor antagonist monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five year follow-up study","author":"Ter Haar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3899\/jrheum.131503","article-title":"Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors","volume":"41","author":"Wallace","year":"2014","journal-title":"J Rheumatol"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/art.34343","article-title":"Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis","volume":"64","author":"Wallace","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial","volume":"70","author":"Tynjala","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/annrheumdis-2018-213902","article-title":"Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial","volume":"78","author":"Hissink Muller","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/ard.2006.055111","article-title":"Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N Engl J Med"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","article-title":"ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis","volume":"77","author":"Quartier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/acr.22649","article-title":"Impact of antiinflammatory treatment on the onset of uveitis in juvenile idiopathic arthritis: longitudinal analysis from a nationwide pediatric rheumatology database","volume":"68","author":"Tappeiner","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.autrev.2011.07.001","article-title":"Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases","volume":"11","author":"Miserocchi","year":"2011","journal-title":"Autoimmun Rev"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.39940","article-title":"Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients","volume":"69","author":"Calvo-Rio","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R46-20230829","first-page":"30462","article-title":"Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis","volume":"S0049-0172","author":"Heiligenhaus","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrrheum.2010.142","article-title":"The safety profile of biologic therapies for juvenile idiopathic arthritis","volume":"6","author":"Hashkes","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"R48-20230829","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.34458","article-title":"Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R49-20230829","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2017","journal-title":"N Engl J Med"},{"key":"R50-20230829","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/acr.22087","article-title":"2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications","volume":"65","author":"Ringold","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R51-20230829","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/art.27511","article-title":"Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration","volume":"62","author":"Diak","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R52-20230829","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1002\/art.27741","article-title":"Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study","volume":"62","author":"Simard","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R53-20230829","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.34348","article-title":"Rates of malignancy associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R54-20230829","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/rheumatology\/keq361","article-title":"Report on malignancies in the German juvenile idiopathic arthritis registry","volume":"50","author":"Horneff","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R55-20230829","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/acr.21709","article-title":"Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents","volume":"64","author":"Nordstrom","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R56-20230829","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/nrrheum.2010.199","article-title":"Pediatric rheumatology: JIA, treatment and possible risk of malignancies","volume":"7","author":"Ruperto","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"R57-20230829","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/ket318","article-title":"Juvenile idiopathic arthritis and malignancy","volume":"53","author":"Ruperto","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R58-20230829","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-018-1780-z","article-title":"Pharmacovigilance injuvenile idiopathic arthritispatients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries","volume":"20","author":"Swart","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"R59-20230829","first-page":"1384","article-title":"Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis","volume":"65","author":"Beukelman","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R60-20230829","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00296-014-3197-6","article-title":"Incidence of herpes zoster infections in jia patients","volume":"35","author":"Nimmrich","year":"2015","journal-title":"Rheumatol Int"},{"key":"R61-20230829","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/jpids\/piu078","article-title":"Herpes virus infections during treatment with etanercept in juvenile idiopathic arthritis","volume":"5","author":"Nicolai","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R62-20230829","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12969-016-0095-3","article-title":"Clinical course and therapeutic approach to varicella zoster virus infection in children with rheumatic autoimmune diseases under immunosuppression","volume":"14","author":"Leuvenink","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"R63-20230829","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jpeds.2018.08.065","article-title":"Risk of serious infections associated with biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analyses","volume":"204","author":"Aeschlimann","year":"2019","journal-title":"J Pediatr"},{"key":"R64-20230829","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10067-018-4304-y","article-title":"Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind","volume":"38","author":"Scott","year":"2019","journal-title":"Clin Rheumatol"},{"key":"R65-20230829","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S2352-4642(19)30027-6","article-title":"Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study","volume":"3","author":"Consolaro","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"key":"R66-20230829","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"issue":"(Suppl 1 (44))","key":"R67-20230829","first-page":"185","article-title":"Pharmacokinetics, safety and tolerability of tofacitinib in paediatric patients from two to less than eighteen years of age with juvenile idiopathic arthritis","volume":"15","author":"Ruperto","year":"2017","journal-title":"Pediatr Rheumatol"},{"key":"R68-20230829","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"R69-20230829","doi-asserted-by":"crossref","first-page":"e000546","DOI":"10.1136\/rmdopen-2017-000546","article-title":"Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis","volume":"3","author":"Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"R70-20230829","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11926-018-0792-7","article-title":"JAK inhibitors in rheumatology: implications for paediatric syndromes?","volume":"20","author":"Kerrigan","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"R71-20230829","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","article-title":"Sarilumab, a fully human monoclonal antibody against IL-6Ra in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial","volume":"73","author":"Huizinga","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R72-20230829","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2013-205137","article-title":"Sirukumab, a human antiinterleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R73-20230829","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/annrheumdis-2011-200704","article-title":"A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate","volume":"71","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R74-20230829","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"key":"R75-20230829","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"R76-20230829","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"24","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"R77-20230829","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1303006","article-title":"Therapies for active rheumatoid arthritis after methotrexate failure","volume":"369","author":"O\u2019Dell","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T07:10:42Z","timestamp":1693293042000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":77,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000632","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}